Form 4: Arcus Biosciences COO Sells Shares After Option Exercise

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, exercised stock options and subsequently sold 50,292 shares of common stock under a Rule 10b5-1 trading plan.

Summary

• Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, Inc. (RCUS), reported transactions involving the exercise of stock options and subsequent sale of common stock.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan.
• On October 6, 2025, Jarrett exercised options to acquire 12,500 shares of common stock at an exercise price of $1.2276 per share.
• Immediately following the exercise on October 6, 2025, 12,500 shares were sold at a weighted average price of $14.5441, with prices ranging from $14.40 to $14.72.
• On October 8, 2025, Jarrett exercised options to acquire an additional 37,792 shares of common stock at an exercise price of $1.2276 per share.
• Concurrently, on October 8, 2025, 37,792 shares were sold at a weighted average price of $15.0458, with prices ranging from $15.00 to $15.16.
• The total number of shares acquired through option exercises and subsequently sold across both dates was 50,292.
• Following these transactions, Jarrett beneficially owns 214,232 shares of common stock directly and 130,874 stock options directly.
• The reported beneficial ownership includes 863 shares purchased on May 30, 2025, through the Company's Employee Stock Purchase Plan.
• All exercised options were fully vested and currently exercisable.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports routine insider transactions (option exercises and sales) executed under a pre-established 10b5-1 trading plan, which is a common practice for executives managing their equity compensation. It does not provide new fundamental information about the company's operations or future prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• The significant difference between the option exercise price ($1.2276) and the sale prices (average $14.5441 and $15.0458) indicates a substantial profit for the reporting person.

Negatives

• The sale of a significant number of shares by a Chief Operating Officer, even if planned, could be perceived as a lack of conviction by some investors, though mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the insider selling, but the pre-arranged nature of the 10b5-1 plan generally mitigates concerns that the sales are based on new, adverse material information.

Key Dates

Recommendation

The filing reports routine insider transactions (option exercises and sales) executed under a pre-established 10b5-1 trading plan. While insider selling can sometimes be a negative signal, the pre-planned nature mitigates concerns about it being based on new, adverse information. It does not provide new fundamental information about the company's operations or future prospects to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Arcus Biosciences, RCUS, Form 4, insider trading, stock options, 10b5-1 plan, Jennifer Jarrett, COO, equity sales